Acquired by Entellus Medical. Developer of a medical implant designed to treat nasal-valve collapse. The company's LATERA Absorbable nasal implant addresses one of the common, causes of nasal obstruction, nasal valve collapse caused by weakened lateral wall cartilage, providing a minimally invasive option for ENTs and facial plastic surgeons to treat nasal airway obstruction.
Location: United States, California, Menlo Park
Total raised: $63.5M
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.03.2016 | Series C | $45M | - |
| 20.04.2015 | Series B | $18.5M | - |
Mentions in press and media 9
| Date | Title | Description |
| 07.08.2016 | Startup wants to advance minimally invasive device to resolve nasal obstruction | The most effective treatment for nasal obstruction is also the most invasive, Spirox CEO Duke Rohlen said during a phone interview. Rhinoplasty (also known as a nose job) is performed to install grafts inside the nose. These so-called batte... |
| 15.03.2016 | Spirox, Inc. Announces Closing of $45MM Series C Financing | MENLO PARK, Calif.--(BUSINESS WIRE)-- Spirox Inc., a privately held medical device company, announced today the closing of a $45 million Series C round of financing led by KKR, a leading global investment firm. In leading the round, KKR j... |
| 15.03.2016 | Spirox Closes $45M Series C Financing | Spirox, Inc., a Menlo Park, CA-based medical device company, closed a $45m Series C round of financing. The round was led by KKR, with participation from new investor HealthQuest Capital and existing shareholders Aisling Capital, Aperture V... |
| 15.03.2016 | Spirox, Inc. Announces Closing of $45MM Series C Financing | MENLO PARK, Calif.–(BUSINESS WIRE)–Spirox Inc., a privately held medical device company, announced today the closing of a $45 million Series C round of financing led by KKR, a leading global investment firm. In leading the round, KKR joins ... |
| 15.03.2016 | Spirox closes $45M Series C for its device used by Ear, Nose and Throat physicians | Spirox is looking to make treating these conditions with a minimally invasive approach possible with its device. The financing round was led by global investment firm KKR as well as HealthQuest Capital, Aisling Capital, Aperture Venture Par... |
| 20.04.2015 | Spirox Closes $18.5M Series B Financing | Spirox Inc., a Menlo Park, CA-based medical device company, closed an $18.5m Series B round of financing. The round was led by Venrock and Aisling Capital with participation from existing investors Aperture Venture Partners, Correlation Ven... |
| 20.04.2015 | Spirox, Inc. Announces Closing of $18.5MM Series B Financing | MENLO PARK, Calif., April 20, 2015 /PRNewswire/ — Spirox Inc., a privately held medical device company, announced today the closing of an $18.5 million Series B round of financing led by Venrock and Aisling Capital. Existing investors Apert... |
| - | Startup wants to advance minimally invasive device to resolve nasal obstruction | The Latera implant, seen in tweezer, with the delivery device. Replacing a complicated surgery with a minimally invasive approach is a tried and true formula in medtech. Menlo Park, California-based startup Spirox is aiming to do that with ... |
| - | Spirox closes $45M Series C for its device used by Ear, Nose and Throat physicians | California-based Spirox Inc. announced today that it has finalized a $45 million Series C round of financing, which will be used to move forward with its minimally invasive system to be used by Ear, Nose and Throat (ENT) physicians and plas... |